Floatz logo

TEIKOPLANIN

Solid Tumors

Hospital Universitari Vall d'Hebron Research InstitutemixturePhase 4 / ApprovedActive
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

207 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Ankara Etlik City Hospital
Phase 2BB
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Ribociclib
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 4B
PREDNISONE TABLETS
The First Affiliated Hospital of Soochow University
Phase 3B

View all 50 →

Same molecule, other indications

TEIKOPLANIN is also rated in:

sclerosing cholangitisDormant
BB
Indicative ·
69 / 100
View asset →
Febrile Neutropenia (FN)Dormant
BB
Indicative ·
65 / 100
View asset →
Pediatric CancerDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →